Literature DB >> 7609540

Plasma antioxidant depletion after cardiopulmonary bypass in operations for congenital heart disease.

L A Pyles1, J E Fortney, J J Kudlak, R A Gustafson, S Einzig.   

Abstract

We describe the use of two in vitro tests to characterize plasma antioxidant capacity at the time of cardiac bypass in operations for congenital heart disease in 30 patients aged 3 days to 16 years (average 4.4 +/- 0.9 years [standard error]). Bypass and crossclamp time, circuit volume, and type of operation were recorded for each patient. First, a test of plasma radical antioxidant power measured chain breaking (secondary) antioxidant capacity of plasma to prevent oxidation of linoleic acid in vitro. Second, overall ability of plasma to prevent lipid peroxidation was assessed by a classic test of plasma inhibition of malondialdehyde formation in a beef brain homogenate. Plasma total radical antioxidant power level at baseline was 0.74 +/- 0.03 mumol/ml plasma, which decreased to 0.15 +/- 0.05 mumol/ml plasma after bypass (p < 0.001) and 0.26 +/- 0.08 mumol/ml plasma with recovery (n = 18, p < 0.001). Analysis of variance of postbypass total radical antioxidant power value showed age (p = 0.0002, r = 0.63) and bypass time (p = 0.009, r = 0.4677) to be significant factors. Pump prime volume in milliliters per kilogram and preoperative hemoglobin value were not significant factors. Beef brain malondialdehyde formation in vitro was limited 92% +/- 3% by normal plasma before operation versus 53% +/- 5% after operation (p < 0.001) and 51% +/- 5% at recovery after arrival in the pediatric intensive care unit (p < 0.001). Analysis of variance of the changes from before to after operation showed age p = 0.0015, r = 0.55) and bypass time (p = 0.033, r = 0.39) to be significant factors. Thus antioxidant capacity of plasma is significantly diminished after cardiopulmonary bypass in children. Young patient age and long duration of cardiopulmonary bypass are identified as factors that correlate positively with depletion of antioxidant capacity with bypass.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609540     DOI: 10.1016/S0022-5223(05)80022-4

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Extracorporeal membrane oxygenation induced cardiac dysfunction in newborn lambs.

Authors:  Lee A Pyles; Robert A Gustafson; James Fortney; Stanley Einzig
Journal:  J Cardiovasc Transl Res       Date:  2010-09-17       Impact factor: 4.132

2.  Protective effect of silymarin during coronary artery bypass grafting surgery.

Authors:  Tagreed Altaei
Journal:  Exp Clin Cardiol       Date:  2012

3.  Association Between Hyperoxemia and Increased Cell-Free Plasma Hemoglobin During Cardiopulmonary Bypass in Infants and Children.

Authors:  Catherine Gretchen; Hϋlya Bayir; Patrick M Kochanek; Kristine Ruppert; Melita Viegas; David Palmer; Nahmah Kim-Campbell
Journal:  Pediatr Crit Care Med       Date:  2022-02-01       Impact factor: 3.624

4.  Effect of Ligusticum wallichii aqueous extract on oxidative injury and immunity activity in myocardial ischemic reperfusion rats.

Authors:  Qiao Zengyong; Ma Jiangwei; Liu Huajin
Journal:  Int J Mol Sci       Date:  2011-03-18       Impact factor: 5.923

Review 5.  Strategies to prevent intraoperative lung injury during cardiopulmonary bypass.

Authors:  Efstratios E Apostolakis; Efstratios N Koletsis; Nikolaos G Baikoussis; Stavros N Siminelakis; Georgios S Papadopoulos
Journal:  J Cardiothorac Surg       Date:  2010-01-11       Impact factor: 1.637

6.  Comparison of antioxidant reserve capacity of children with acyanotic & cyanotic congenital heart disease.

Authors:  Hale Hatice Temel; Ulas Kumbasar; Esra Büber; Yasemin Aksoy; Sabanur Cavdar; Rıza Dogan; Metin Demircin; İlhan Pasaoglu
Journal:  Indian J Med Res       Date:  2020-12       Impact factor: 2.375

Review 7.  Oxidative Stress after Surgery on the Immature Heart.

Authors:  Daniel Fudulu; Gianni Angelini
Journal:  Oxid Med Cell Longev       Date:  2016-03-31       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.